Robeco Institutional Asset Management B.V. continued to hold its position in Meridian Bioscience Inc. (NASDAQ:VIVO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 267,931 shares of the company’s stock at the end of the second quarter. Robeco Institutional Asset Management B.V.’s holdings in Meridian Bioscience were worth $5,225,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Hancock Holding Co. raised its position in Meridian Bioscience by 11.3% in the first quarter. Hancock Holding Co. now owns 77,394 shares of the company’s stock worth $1,595,000 after buying an additional 7,866 shares in the last quarter. Geode Capital Management LLC raised its position in Meridian Bioscience by 1.3% in the first quarter. Geode Capital Management LLC now owns 339,270 shares of the company’s stock worth $6,992,000 after buying an additional 4,288 shares in the last quarter. Zebra Capital Management LLC raised its position in Meridian Bioscience by 23.9% in the first quarter. Zebra Capital Management LLC now owns 24,898 shares of the company’s stock worth $513,000 after buying an additional 4,802 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Meridian Bioscience by 1.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,118,070 shares of the company’s stock worth $23,043,000 after buying an additional 15,697 shares in the last quarter. Finally, BlackRock Group LTD raised its position in Meridian Bioscience by 4.6% in the first quarter. BlackRock Group LTD now owns 68,586 shares of the company’s stock worth $1,413,000 after buying an additional 3,005 shares in the last quarter. 88.30% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Meridian Bioscience Inc. (NASDAQ:VIVO) traded down 0.57% during midday trading on Friday, reaching $19.15. 335,383 shares of the company were exchanged. The company’s 50-day moving average price is $19.40 and its 200 day moving average price is $19.77. The stock has a market capitalization of $805.95 million, a price-to-earnings ratio of 22.80 and a beta of 1.06. Meridian Bioscience Inc. has a 52-week low of $16.60 and a 52-week high of $21.49.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.22 by $0.01. Meridian Bioscience had a return on equity of 21.51% and a net margin of 17.95%. The firm earned $50.70 million during the quarter, compared to analyst estimates of $52.85 million. During the same quarter in the prior year, the firm earned $0.22 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities analysts predict that Meridian Bioscience Inc. will post $0.86 earnings per share for the current year.

A number of equities analysts recently issued reports on the company. Zacks Investment Research raised Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Wednesday, July 13th. Hilliard Lyons lowered Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Friday, July 29th. Finally, Canaccord Genuity reissued a “hold” rating and set a $20.00 price target on shares of Meridian Bioscience in a report on Monday, August 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. Meridian Bioscience presently has a consensus rating of “Hold” and an average target price of $21.25.

About Meridian Bioscience

Meridian Bioscience, Inc (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

5 Day Chart for NASDAQ:VIVO

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.